Evidence map›Paper›PMID 19628431›Full record

ReviewCurrent opinion in pharmacology2009

Extracellular nucleotides as negative modulators of immunity.

Francesco Di Virgilio, Jean-Marie Boeynaems, Simon C Robson

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 120 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Schistosoma mansoni and the purinergic halo.Trends in parasitology · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Signaling of the Purinergic System in the Joint.Frontiers in pharmacology · 2019
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Francesco Di VirgilioDepartment of Experimental and Diagnostic Medicine, Section of General Pathology, University of Ferrara, Italy. fdv@unife.it
Jean-Marie Boeynaems
Simon C Robson
Beth Israel Deaconess Hospital · USUniversité Libre de Bruxelles · BEUniversity of Ferrara · IT

Funding

XENOGRAFT TOLERANCE THROUGH MIXED CHIMERISMP01AI045897 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Megan Sykes · 2000 to 2026
$71.9M
Thromboregulatory strategies to prolong xenograft survival.U01AI066331 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2005 to 2009
$4.1M
Purinergic ThromboregulationR01HL094400 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2009 to 2010
$1.4M
NHLBI NIH HHS R01 HL094400NIAID NIH HHS P01 AI045897NIAID NIH HHS U01 AI066331Telethon GGP06070
6 · The paper itself

Abstract

Nucleotides are well known for being the universal currency of intracellular energy transactions, but over the past decade it has become clear that they are also ubiquitous extracellular messengers. In the immune system there is increasing awareness that nucleotides serve multiple roles as stimulants of lymphocyte proliferation, ROS generation, cytokine and chemokine secretion: in one word as pro-inflammatory mediators. However, although often neglected, extracellular nucleotides exert an additional more subtle function as negative modulators of immunity, or as immunodepressants. The more we understand the peculiar biochemical composition of the microenvironment generated at inflammatory sites, the more we appreciate how chronic exposure to low extracellular nucleotide levels affect immunity and inflammation. A deeper understanding of this complex network will no doubt help design more effective therapies for cancer and chronic inflammatory diseases.

Indexed as

AnimalsAntineoplastic AgentsExtracellular SpaceHumansImmunosuppressive AgentsInflammation MediatorsLymphocyte ActivationNucleotidesSignal TransductionAntineoplastic AgentsImmunosuppressive AgentsInflammation MediatorsNucleotides

Identifiers

PMID19628431
PMCPMC4158611
OpenAlexW2034321048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.